Hydrochloric Acid

Hydrochloric Acid

SCHEMBL754670

CC(C)CC(C)(CC(C)C)OC(C)NC(C)(C)c1ccccc1.Cl

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1F known ✓ O60840 2/20 0.33
OPRK1 known ✓ P41145 2/20 0.33
CACNA1D known ✓ Q01668 2/20 0.33
KCNH2 known ✓ Q12809 2/20 0.33
CACNA1S known ✓ Q13698 2/20 0.33
CACNA1C known ✓ Q13936 2/20 0.33
CHRM2 known ✓ P08172 1/20 0.33
CHRM1 known ✓ P11229 1/20 0.33
ADRA2B known ✓ P18089 1/20 0.33
CHRM3 known ✓ P20309 1/20 0.33
ADRA1A known ✓ P35348 1/20 0.33
HRH1 known ✓ P35367 1/20 0.33
SLC6A3 known ✓ Q01959 1/20 0.33
SCN5A known ✓ Q14524 1/20 0.33
GAA known ✓ P10253 2/20 0.31
GRIN2D known ✓ O15399 2/20 0.31
GRIN1 known ✓ Q05586 2/20 0.31
GRIN2A known ✓ Q12879 2/20 0.31
GRIN2B known ✓ Q13224 2/20 0.31
GRIN2C known ✓ Q14957 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012096 0.98 CACNA1F (0.33) CACNA1FOPRK1CACNA1DKCNH2CACNA1S
Hydrochloric Acid SCHEMBL9796807 0.76 KCNN4 (0.36) CACNA1FOPRK1CACNA1DKCNH2CACNA1S
Hydrochloric Acid SCHEMBL10708769 0.74 KCNN4 (0.35) CACNA1FOPRK1CACNA1DKCNH2CACNA1S
Hydrochloric Acid SCHEMBL5029119 0.71 SLC6A2 (0.34) KCNH2SLC6A3
SCHEMBL5402653 0.69 TDP1 (0.46) CACNA1FOPRK1CACNA1DKCNH2CACNA1S
SCHEMBL24453542 0.67 CACNA1F (0.43) CACNA1FOPRK1CACNA1DKCNH2CACNA1S
Hydrochloric Acid SCHEMBL7748984 0.67 SLC6A2 (0.32) KCNH2
SCHEMBL9324548 0.67 KDM4E (0.34) MAPK1GAATAAR1ALDH1A1ALOX15
Hydrochloric Acid SCHEMBL11534150 0.66
Hydrochloric Acid SCHEMBL166562 0.66 ELANE (0.36) KCNH2GAASMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118556090-A Water-soluble and/or water-swellable hybrid polymers 科莱恩国际有限公司 2024-08-27 CN disclosed
CN-116528830-A Long chain esters for cosmetic treatment of skin 科莱恩国际有限公司 2023-08-01 CN disclosed
CN-110300573-B Use of biobased polymers in cosmetic, dermatological or pharmaceutical compositions 科莱恩国际有限公司 2023-07-25 CN disclosed
CN-116419744-A Opacifying agent composition 科莱恩国际有限公司 2023-07-11 CN disclosed
US-9622959-B2 Cross-linked polymere CLARIANT INTERNATIONAL LTD. (CH) 2017-04-18 US disclosed
US-9596849-B2 Composition containing sorbitan monocaprylate and alcohol CLARIANT INTERNATIONAL LTD. (CH) 2017-03-21 US disclosed
US-20160206542-A1 COSMETIC OR DERMATOLOGICAL COMPOSITIONS COMBINING COSMETIQUES RETINALDEHYDE AND GLYCYLGLYCINE OLEAMIDE AND THE COSMETIC OR DERMATOLOGICAL USES THEREOF PIERRE FABRE DERMO-COSMETIQUE (FR) 2016-07-21 US disclosed
US-9101785-B2 Use of 2,3-dihydroxypropyl dodecanoate for treating seborrhoea PIERRE FABRE DERMO-COSMETIQUE (FR) 2015-08-11 US disclosed
US-8969390-B2 Composition containing sorbitan monocaprylate and antimicrobial substances CLARIANT FINANCE (BVI) LIMITED (VG) 2015-03-03 US disclosed
US-8961944-B2 Use of delta-tocopheryl-carbohydrate as a depigmenting agent PIERRE FABRE DERMO-COSMETIQUE (FR) 2015-02-24 US disclosed
US-20120101135-A1 COMPOSITION CONTAINING SORBITAN MONOCAPRYLATE AND ANTIMICROBIAL SUBSTANCES CLARIANT FINANCE (BVI) LIMITED (VG) 2012-04-26 US disclosed
US-20120093749-A1 USE OF DELTA-TOCOPHERYL-CARBOHYDRATE AS A DEPIGMENTING AGENT PIERRE FABRE DERMO-COSMETIQUE (FR) 2012-04-19 US disclosed
EP-2429485-A2 USE OF DELTA-TOCOPHERYL-CARBOHYDRATE AS A DEPIGMENTING AGENT Pierre Fabre Dermo-Cosmétique (FR) 2012-03-21 EP disclosed
US-20110104085-A1 Cosmetic Or Pharmaceutical Compositions Comprising Modified Polysiloxanes With At Least One Carbamate Group CLARIANT FINANCE (BVI) LIMITED (VG) 2011-05-05 US disclosed
WO-2010130776-A2 USE OF DELTA-TOCOPHERYL-CARBOHYDRATE AS A DEPIGMENTING AGENT PIERRE FABRE DERMO-COSMETIQUE (FR) 2010-11-18 WO disclosed
WO-2009149879-A1 COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING MODIFIED POLYSILOXANES WITH AT LEAST ONE CARBAMATE GROUP CLARIANT INTERNATIONAL LTD (CH) 2009-12-17 WO disclosed
EP-1972330-A2 Cosmetic or pharmaceutical compositions comprising modified polysiloxanes with at least one carbamate group CLARIANT INTERNATIONAL LTD. (CH) 2008-09-24 EP disclosed
US-20070031361-A1 Cosmetic, pharmaceutical and dermatological preparations comprising homopolymer and/or copolymer waxes of the monomers ethylene and/or propylene HERRMANN HANS-FRIEDRICH 2007-02-08 US disclosed
US-20060188459-A1 Cosmetic, pharmaceutical or dermatological preparations comprising copolymer waxes HEINRICHS FRANZ-LEO 2006-08-24 US disclosed
US-20060104940-A1 Cosmetic, pharmaceutical and dermatological preparations comprising copolymer waxes CLARIANT GMBH 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070031361-A1 Cosmetic, pharmaceutical and dermatological preparations comprising homopolymer and/or copolymer waxes of the monomers ethylene and/or propylene PMS2, MSH2, PGM2 CACNA1F 2667/4885OPRK1 3769/4885CACNA1D 2165/4885
US-20060104940-A1 Cosmetic, pharmaceutical and dermatological preparations comprising copolymer waxes CUTA, ACMSD, DEGS1 CACNA1F 3758/4885OPRK1 1609/4885CACNA1D 4259/4885
US-20110104085-A1 Cosmetic Or Pharmaceutical Compositions Comprising Modified Polysiloxanes With At Least One Carbamate Group KDM1A, KDM6A, KDM2A CACNA1F 3284/4885OPRK1 3617/4885CACNA1D 3048/4885
US-20120093749-A1 USE OF DELTA-TOCOPHERYL-CARBOHYDRATE AS A DEPIGMENTING AGENT TTPA, ECH1, GLA CACNA1F 3521/4885OPRK1 3397/4885CACNA1D 3951/4885
US-20060188459-A1 Cosmetic, pharmaceutical or dermatological preparations comprising copolymer waxes CUTA, DEGS1, DSG1 CACNA1F 3104/4885OPRK1 3306/4885CACNA1D 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.